Company Profile For Endo Pharmaceuticals Holdings Inc

Endo Pharmaceuticals Holdings Inc., is a specialty pharmaceutical company in pain management. The Company is engaged in the research, development, sales and marketing of branded and generic pharmaceutical products primarily to treat and manage pain. Its portfolio of branded products includes Lidoderm, Opana ER, Percocet, and Frova. It concentrates on generics that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing. During the year ended December 31, 2008, the branded products and non-branded generic portfolio comprised approximately 93% and 7%, respectively, of the Company's net sales. It markets its branded pharmaceutical products to prescribing physicians in pain management, neurology, surgery, anesthesiology, oncology and primary care. In March 2009, Endo Pharmaceuticals Holdings Inc. completed the acquisition of Indevus Pharmaceuticals, Inc.

BRIEF: For the six months ended 30 June 2009, Endo Pharmaceutical's revenues rose 19% to $708.4M. Net income fell 41% to $69.1M. Revenues reflect increased sales of Opana due to continued prescription growth and higher sales of other brand from acquisition of Indevus Pharmaceuticals Inc. Net income was offset by an increase in costs of sales and the presence of expenses related to acquisitions.